Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD). However, there is considerable variability in reported factors. We hence evaluated patient, transplantation and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables identified as significant in multivariate analysis of overall survival and non relapse mortality (NRM) (age, prior acute GVHD, time from transplant to cGvHD, donor type, disease status at transplant, GvHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score and platelet count) were used to build the cGVHD risk score. Six risk groups (RG) were identified. The 5 year NRM was 5% (1-9%) in RG1, 20% (19-23%) in RG2, 33% (29-37%) in RG3, 43% (40-46%) in RG4, 63% (53-74%) in RG5 and 72%
Introduction:
Chronic graft-versus-host disease (cGVHD) is the leading cause of late morbidity and mortality after allogeneic hematopoietic cell transplant (HCT) 1, 2 . Several risk factors predicting survival in patients with cGVHD have been reported [3] [4] [5] [6] [7] [8] [9] [10] [11] . These include recipient and donor age . Of these, the most consistent factors across studies remains thrombocytopenia at diagnosis of cGVHD and progressive onset of disease, with studies reporting variability in other factors reported.
We proposed to identify a simple model using readily available patient, disease and HCT characteristics in conjunction with objective variables at diagnosis of cGVHD (thrombocytopenia, serum bilirubin, KPS, time to onset of cGVHD and type of onset of cGVHD) to develop a risk score in a cohort of 5343 patients with cGVHD who registered with CIBMTR. We hypothesized that development of a simple cGVHD risk score using the largest available multi-center cohort could lead to better generalizability and easier identification of high risk populations for therapeutic trials or clinical use. In the current study, we evaluated this cohort of patients with cGVHD for overall survival and NRM and incorporated multiple variables to develop a new risk score model that predicts overall survival and non relapse mortality (NRM) for patients with cGVHD.
Material and Methods:
Center Registry (ABMTR), and the National Marrow Donor Program (NMDP). The CIBMTR is a voluntary organization involving more than 500 transplant centers that have collaborated to share patient data and conduct scientific studies. Quality and compliance of data submission are monitored by computerized checks for errors, physician reviews, and on-site audits.
For personal use only. on October 24, 2017. by guest www.bloodjournal.org From Patient selection: The study population included all patients who received an allogeneic transplant from a related or unrelated donor (URD) including umbilical cord blood (UCB) for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML) or myelodysplastic disorders (MDS) between [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] and were diagnosed with cGVHD within one year of transplant and were registered with CIBMTR. All surviving recipients who received transplants from URDs included in this analysis were retrospectively contacted and provided informed consent for participation in the NMDP research program. Informed consent for retrospective data analysis was waived by the NMDP institutional review board for all deceased patients. Surviving patients who did not provide signed informed consent to allow analysis of their clinical data were excluded. To adjust for potential bias introduced by exclusion of non consenting surviving patients, a corrective action plan (CAP)-modeling process randomly excluded approximately the same percentage of deceased patients using a biased coin randomization with exclusion probabilities based on characteristics associated with not providing consent for use of data in survivors. The study includes a total of 5343 HCT recipients with cGVHD.
Study Endpoints and Definitions
The primary endpoints of the study were overall survival and non relapse mortality (NRM). Predictive factors significant in the model for overall survival were used to develop a risk score for recipients with cGVHD. Overall survival was estimated from onset of cGVHD. Death from any cause was treated as event. Surviving patients were censored at the date of last contact. NRM was defined as death in continuous remission. The event was summarized by the cumulative incidence estimate with relapse as the competing risk. Grade II-IV acute GVHD was graded according to IBMTR criteria based on the pattern of severity of abnormalities in skin, gastrointestinal tract, and liver
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. cGVHD was diagnosed according to standard CIBMTR criteria 7, 13 ., which includes all patients with clinical criteria of cGvHD 13 with or without positive histology, irrespective of time of onset of symptoms. Data required to generate an NIH score were not prospectively collected by the CIBMTR during the study period. 14 We defined reduced intensity/ non-myeloablative regimens as follows: busulfan dose <9mg/kg, melphalan dose <150mg/m 2 , and total body irradiation dose <500 cGy (single or fractionated) or 500-800 cGy (fractionated)
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.
Statistical Analysis
Variables related to patient, disease, and transplant characteristics were described using descriptive statistics. 
Results

Patient characteristics
The study cohort included 5343 recipients with cGVHD. Table 1 demonstrates the patient, disease, transplant and cGVHD specific variables for these recipients. The median age at HCT was 36 years (range <1 -72), the majority (55%) received a HCT for acute leukemia, 34% for CML and 11% for MDS. Majority were transplanted in early disease status (55%) Thirty seven % received a HCT from an HLA-identical sibling donor, 4% from other related donors and 54% from an URD donor (including 127 recipients of unrelated umbilical cord blood). Amongst the cGVHD specific variables, the median time from transplant to cGVHD onset was 5 months (range 1-11 months), 43%
had progressive onset of disease and 36% had a platelet count of <100 x10 9 /L at diagnosis.
Overall Survival: The probability of overall survival was 72% (95% CI 71-73%) at one year and 55% (95% CI 54-57%) at 5 years. In the multiple regression model, increasing recipient age, presence and higher grade of prior acute GVHD, early onset of cGVHD (< 5 months), higher serum bilirubin at cGVHD onset, lower KPS at cGVHD onset, presence of thrombocytopenia at cGVHD onset (platelet count of <100 x10 prophylaxis and gender mismatch (female donor to male recipient versus male donor to male recipient) were significantly associated with a higher risk of mortality. (Table 2 ).
NRM:
The cumulative incidence of NRM was 21% (95% CI 20-22%) at one year and 31% (95% CI 29-32%) at five years. In the multiple regression model, the same factors identified for overall survival were also identified to be predictive of NRM ( Table 2 ).
As patients with progressive onset of cGVHD were identified to have an earlier time to onset (median 3.6 months) as compared to deno-vo (median 5.2 months) and quiescent cGVHD (median 5.5 months), interaction between time to onset and type of onset was evaluated and found to be non-significant.
Development of cGVHD Risk score:
Using the above identified predictive variables, we next developed a cGVHD risk score for overall survival or NRM. This was done in a data set (n=3550) where all missing or unknown categories were deleted. Ten variables identified as significant in multivariate analysis of overall survival and non relapse mortality (NRM) were used to build the cGVHD risk score. Variable-specific risk scores (VSRC) were constructed for each variable based on the relative risk of each category of the variable as detailed in table 3.
The VSRCs were summed for each patient to assign an overall risk score (ORS). Risk groups (RG) were assigned based on the overall risk score as follows: RG1: ORS 0-2; RG2: ORS 3-6; RG 3: ORS 7-8; RG 4: ORS 9-10; RG 5: ORS 11; RG6: ORS > 12. Table 4 gives the 5 year overall survival and NRM estimates for each group.
The results of risk stratification by cGVHD risk score are also given in figures 1 (Overall survival), and 2 (NRM). As shown, the probability of overall survival at 5 years was 91% (95% CI:85-97%) in RG1 followed by 67% (95% CI:65-69%) in RG2, 51% (95% CI:46-55%) in RG3, 40% (95% CI: 37-43%) in RG4, 21% (95% CI: 12-30%) in RG5 and 4% (95% CI: 0-9%) in RG6.
The cumulative incidence of NRM at 5 years 5 year NRM was 5% (95% CI: 1-9%) in RG1, 20% (95% CI: 19-23%) in RG2, 33% (95% CI: 29-37%) in RG 3, 43% (95% CI:
40-46%) in RG4, 63% (95% CI: 53-74%) in RG5 and 72% (95% CI: 59-85%) in RG6.
Discussion
Our analysis of the largest cohort of cGVHD patients to date, has evaluated patient and HCT related factors as well as objective cGVHD specific variables to develop a cGVHD risk score. We identified six different risk groups based on sum of risk factors that demonstrated a difference in overall survival and NRM.
Prior studies have identified several variables pertaining to organ involvement at onset of cGVHD as significant for higher mortality. For example in a study evaluating a clinical grading system for cGVHD 4 extensive skin involvement, thrombocytopenia and progressive onset of cGVHD were identified to be significant predictors of disease free survival. The disease free survival in the four risk groups was 82%, 68%, 34%, and 3%
at 10 years. The performance of this prognostic score was tested in 1105 patients from four cohorts 3 . The extent of skin involvement was quantified in three cohorts using available data. In this dataset, the mortality hazard associated with extensive skin involvement was lower in each of these test samples compared with the learning sample.
In , evaluating prognostic criteria for NRM in a cGVHD cohort as defined by the NIH consensus criteria, the same six variables reported in their prior analysis (as given above) were found to be significant, except for donor age at transplant. However, both of these studies included recipients of myeloablative transplants with bone marrow as the source of stem cells in approximately 80% of recipients.
With recent changes in transplant strategies, there is increasing use of alternative donors including umbilical cord blood; more frequent use of peripheral blood stem cell and reduced intensity or non-myeloablative conditioning; and older recipient age at transplant. Hence, we addressed this question in a large multi-center cohort including all donor sources, all graft sources and all ages. We included patients who underwent a non-myeloablative or reduced intensity transplant as well, but this constituted only 11% of our cohort. Similar to the recent analysis, we did not find an impact of graft source on NRM or overall survival. In the study by Stewart et al With recent improvements in supportive care, a lower NRM in the recent years is anticipated. However, we did not find an impact of the year of transplant on NRM or overall survival. This may be related to changing patient populations over the years, with older patients undergoing a transplant in recent years which could account for a higher mortality 11, 19 . Our patient population is selected from a time period when NIH consensus criteria were not applicable and we could not test the impact of NIH staging and classification on survival and NRM. Nevertheless, variables identified in this scoring schema can be easily obtained and applied in patients at the time of cGVHD presentation. In cGVHD trials specifically this system may be used as complementary to the new NIH staging criteria for the purpose of better patient population description and the concurrent validation relative to survival and NRM. We also recognize that persistent acute GVHD may have many features similar to progressive onset cGVHD, we hence repeated the analysis after excluding patients with early progressive onset cGVHD (patients with progressive onset, <130 days from HCT).
The risk score remained similarly applicable for both overall survival and NRM in this population.
Our study utilizes the largest available multi-center cohort of cGVHD patients to develop a cGVHD risk score using patient characteristics that are easily available at the time of cGVHD diagnosis. The score demonstrates high significance in predicting both overall survival and NRM. The score, if validated, will provide a practical tool to help identify high risk patients for further therapy and enrollment in clinical trials.
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